TOT Biopharm
Oncology CDMO for antibody-drug conjugates and biologics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | N/A | IPO | |
| Total Funding | 000k | ||
| CNY | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (50 %) | 239 % | 479 % | 77 % | 41 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (530 %) | (1136 %) | (287 %) | (1 %) | 3 % | 9 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (661 %) | (1283 %) | (342 %) | (11 %) | (5 %) | 3 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 422 % | 1046 % | 281 % | 34 % | 13 % | 7 % |
Source: Company filings or news article
Related Content
TOT Biopharm is a biopharmaceutical company specializing in providing Contract Development and Manufacturing Organization (CDMO) services with a focus on oncology. Founded in 2010 and headquartered in Suzhou Industrial Park, China, the company has established itself as a key partner for pharmaceutical companies in the development and manufacturing of biologics, particularly antibody-drug conjugates (ADCs). The company was listed on the Hong Kong Stock Exchange in November 2019.
The company was co-founded by individuals including Ms. Yeh-Huang, Chun-Ying, who served as the general manager from its inception until late 2020 and now acts as Vice Chairperson. The current CEO, Dr. Liu, Jun, joined in 2016 and has been leading the company's strategic shift towards a CDMO-focused business model. Under his leadership, the company has seen significant revenue growth.
TOT Biopharm's business model centers on providing one-stop, end-to-end CDMO solutions, from drug research and development to commercial-scale GMP manufacturing. This integrated service model helps clients accelerate the development of biologics and ADCs by performing key processes like antibody manufacturing, conjugation, and drug product formulation at a single site, which reduces transfer costs and regulatory risks. The company primarily serves domestic and international pharmaceutical firms. Its revenue is generated from these CDMO services and has also been supplemented by product sales and licensing fees.
The company's core services are built around its integrated technology platforms for therapeutic monoclonal antibodies, ADCs, and gene engineering-based therapeutics. Its main product and service area is the development and manufacturing of ADCs. TOT Biopharm has also developed its own drug pipeline, including Pusintin® (bevacizumab injection, TAB008), an anti-tumor biosimilar approved for marketing in China for non-small cell lung cancer and metastatic colorectal cancer. The company's manufacturing facilities in Suzhou feature a total production capacity of over 20,000 liters and specialized workshops for ADC production.
Keywords: antibody-drug conjugates, biologics, CDMO, oncology, biopharmaceutical manufacturing, monoclonal antibodies, GMP production, drug development, process development, cancer therapy, biosimilar, clinical-stage, commercial manufacturing, pharmaceutical services, Suzhou, biologics manufacturing, ADC platform, bevacizumab, contract manufacturing, gene therapy